Vertex Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for VERTEX PHARMS INC, and when can generic versions of VERTEX PHARMS INC drugs launch?
VERTEX PHARMS INC has six approved drugs.
There are forty-nine US patents protecting VERTEX PHARMS INC drugs.
There are six hundred and seventy patent family members on VERTEX PHARMS INC drugs in forty-seven countries and sixty-nine supplementary protection certificates in nineteen countries.
Summary for Vertex Pharms Inc
International Patents: | 670 |
US Patents: | 49 |
Tradenames: | 4 |
Ingredients: | 4 |
NDAs: | 6 |
Drugs and US Patents for Vertex Pharms Inc
International Patents for Vertex Pharms Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Singapore | 10201913603Q | ⤷ Sign Up |
Morocco | 54649 | ⤷ Sign Up |
New Zealand | 763453 | ⤷ Sign Up |
Brazil | PI0916877 | ⤷ Sign Up |
Japan | 2021119172 | ⤷ Sign Up |
South Africa | 200809290 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Vertex Pharms Inc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2826776 | 21C1018 | France | ⤷ Sign Up | PRODUCT NAME: TEZACAFTOR ET IVACAFTOR, SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/18/1306 20181106 |
2404919 | C 2016 015 | Romania | ⤷ Sign Up | PRODUCT NAME: LUMACAFTOR SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTUIA, SAU UN PROMEDICAMENT ESTER AL ACESTUIA; NATIONAL AUTHORISATION NUMBER: EU/1/12/1059/001-002; DATE OF NATIONAL AUTHORISATION: 20151119; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/12/1059/001-002; DATE OF FIRST AUTHORISATION IN EEA: 20151119 |
2395002 | 300812 | Netherlands | ⤷ Sign Up | PRODUCT NAME: 3-(6-((1-(2,2-DIFLUOR-1,3-BENZODIOXOL-5-YL)CYCLOPROPAANCARBONYL)AMINO)-3-METHYLPYRIDIN-2-YL)BENZOEZUUR, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/15/1059 20151124 |
2826776 | C202130026 | Spain | ⤷ Sign Up | PRODUCT NAME: UNA COMBINACION DE (A) (R)-1-(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-IL)-N-(1-(2,3-DIHIDROXIPROPIL)-6-FLUORO-2-(1-HIDROXI-2-METILPROPAN-2-IL)-1H-INDOL-5-IL)CICLOPROPANOCARBOXAMIDA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO Y(B) N-(5-HIDROXI-2,4-DITERT-BUTIL-FENIL)-4-OXO-1HQUINOLIN-3-CARBOXAMIDA O UNA SALFARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/18/1306; DATE OF AUTHORISATION: 20181031; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1306; DATE OF FIRST AUTHORISATION IN EEA: 20181031 |
2404919 | C20160015 00195 | Estonia | ⤷ Sign Up | PRODUCT NAME: LUMAKAFTOOR / IVAKAFTOOR;REG NO/DATE: EU/1/15/1059 24.11.2015 |
2404919 | 2016/018 | Ireland | ⤷ Sign Up | PRODUCT NAME: 3-(6-((1-(2,2-DIFLUORO-1,3-BENZODIOXOL-5- YL)CYCLOPROPANECARBONYL)AMINO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID (LUMACAFTOR), OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR AN ESTER PRODRUG THEREOF; REGISTRATION NO/DATE: EU/1/15/1059 20151119 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.